Analysis of serum ErbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer

Cancer Letters

Volumn 152, Issue 1, 2000, Pages 87-95

  Yoshimura, Chie ^a   Nomura, Shosaku ^a   Yamaoka, Manabu ^a   Ohtani, Tetsuji ^a   Matsuzakiz, Tatsunori ^a   Yamaguchi, Kazuyuki ^a   Fukuharal, Shirou ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

ErbB 2; HLA DRB1*0901; HLA DRB1*1302; Lung cancer; Prognostic factor

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; JAPAN; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HLA-DR ANTIGENS; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0034725108     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00437-1     Document Type: Article

References (49)

1. Henderson B.E., Ross R.K., Pike M.C. Toward the primary prevention of cancer. Science. 254:1991;1131-1137.
2. Page A., Nakhle G., Mercier C., Verdant A., Page P., Dontigny L., Allard S., Gauthier J.J., Cossette R. Surgical treatment of bronchiogenic carcinoma. The importance of staining in evaluating late survival. Can. J. Surg. 30:1987;96-99.
3. Little C.D., Nau M.M., Carney D.N., Gazdar A.F., Minna J.D. Amplification and F expression of the c-myx oncogene in human lung cancer cell lines. Nature. 306:1983;194-196.
4. Rodenhuis S., van de Wetering M.L., Mooi W.J., Ever S.C., van Zandwijk N., Box J.L. Mutational activation of the K-ras oncogene: a posible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317:1987;929-935.
5. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.I., Torney L., Robinson R.A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50:1990;5184-5191.
6. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
7. Press M.F., Cordon-Cardo C., Slamon D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 5:1990;953-962.
8. Suda Y., Aizawa S., Furuta Y., Yagi T., Ikawa Y., Saitoh K., Yamada Y., Toyoshima K., Yamamoto T. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with mutated gene (Val659-Glu659). EMBO J. 9:1990;181-190.
9. Rachwal W.J., Bongiorno P.F., Orringer M.B., Whyte R.I., Ethier S.P., Beer D.G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br. J. Cancer. 72:1995;56-64.
10. Mori S., Mori Y., Mukaiyama T., Yamada Y., Sonobe Y., Matsushita H., Sakamoto G., Akiyama T., Ogawa M., Shiraishi M. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Jpn. J. Cancer Res. 81:1990;489-494.
11. Langton B.C., Crenshaw M.C., Chao L.A., Stuart S.G., Akita R.W., Jackson J.E. An antigen immunologically related to the external domain gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER/neu) oncogene. Cancer Res. 15:1991;2593-2598.
12. Leizel K., Teramoto Y., Sampson E., Mauceri J., Langtom B.C., Demers L., Podczaski E., Harvey H., Shamboaugh S., Volas G. Elevated soluble c-erbB2 antigen levels in the serum and suffusions of a proportion of breast cancer patients. J. Clin. Oncol. 9:1992;1436-1443.
13. Rogentine G.N., Dellon A.L., Chretien P.B. Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Awl 9 and HLA-BS. Cancer. 39:1977;2345-2347.
14. Prazak J., Mericka O., Chytry J. Histocompatibility locus antigens (HLA) in the epidermoid type of lung carcinoma. J. Cancer Res. Clin. Oncol. 116:1990;525-527.
15. Romano P.J., Bartholomew M., Smith P.J., Kloszewski F., Stryker J., Houck J., Vesell E.S., antigens H.L.A. influence resistance to lung carcinoma. Hum. Immunol. 31:1991;236-240.
16. Masuko T., Sugahara K., Kozono M., Otsuki S., Akiyama T., Yamamoto T., Toyoshima K., Hashimoto Y. A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. Jpn. J. Cancer Res. 80:1989;10-14.
17. Saga T., Endo K., Akiyama T., Sakahara H., Koizumi M., Watanabe Y., Nakai T., Hosono M., Yamamoto T., Toyoshima K. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res. 51:1991;990-994.
18. Terasaki P.I., McClelland J.D. Microdroplet assay of human serum cytotoxins. Nature. 204:1964;998-1002.
19. Nomura S., Matsuzaki T., Ozaki Y., Yamaoka M., Yoshimura C., Katsura K., Xie G.L., Kagawa H., Ishida T., Fukuhara S. Clinical significant of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood. 91:1998;3616-3622.
20. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell C.J. Jr., Forcier R.J., Edwards R., Headly E., Kim S.H., O'Donnell J.R., O'Dell R., Tornyos K., Kwaan H.C. Effect of sodium warfarin on survival in small cell carcinoma of the lung. J. Am. Med. Assoc. 245:1981;831-835.
21. Lebeau B., Chastang C.L., Brechot J.M., Capron F., Dautzenberg B., Delaisements C., Mornet M., Brun J., Hurde-bourcq J.P., Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 74:1994;38-45.
22. Maurer L.H., Herndon J.E. II, Hollis D.R., Aisner J., Carey R.W., Skarin A.T., Perry M.C., Eaton W.L., Zacharski L.L., Hammond S., Green M.R. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited stage small-cell lung cancer: a cancer and leukemia group B study. J. Clin. Oncol. 15:1997;3378-3387.
23. Junker K., Thomas M., Schulmann K., Klinke F., Bosse U., Muller K.-M. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J. Cancer Res. Clin. Oncol. 123:1997;469-477.
24. Frasci G., Panza N., Comella P., Nicolella G.P., Natale M., Pacilo C., Gravina A., Caputi V., Botti G., Comella G. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann. Oncol. 8:1997;1045-1048.
25. Komaki R., Scott C., Lee J.S., Urtasun R.C., Byhardt R.W., Emami B., Andras E.J., Asbell S.O., Rotman M., Cox J.D. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Am. J. Clin. Oncol. 20:1997;435-440.
26. O'Rourke M.A. Historical review of trials with vinorelbine in non-small-cell lung cancer. Oncology. 11:1997;20-27.
27. Cowley G.P., Smith J., Gusterson B.A. Increased epidermal growth factor receptors on human squamous carcinoma cell lines. Br. J. Cancer. 53:1986;223-229.
28. Hynes N.E., Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1198:1194;165-184.
29. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Lenin W.J., Stuart S.G., Udove H., Ullrich A., Press M.F. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
30. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson D.L., Marks P., McKenzie S., Yin S., Bast R.C. Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
31. Felip E., Lampo J.M.D., Rubio D., Vidal M.T., Colomer R. Overexpression of c-erbB-2 in epithelial ovarian cancer-prognostic value and relationship with response to chemotherapy. Cancer. 75:1995;2147-2152.
32. Kim Y.T., Kim J.W., Lee J.W. c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. Cancer Lett. 132:1998;91-97.
33. Haldane J.S., Hird V., Hughes C.M., Gullick W.J. c-erbB-2 oncogene expression in ovarian cancer. J. Pathol. 162:1990;231-237.
34. Shingleton T.P., Perrone T., Qakley G., Niehans G.A., Carson L., Cha S.S., Strickler J.G. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer. 73:1994;1460-1466.
35. Ford C.H.J., Newman C.E., Mackintosh P. HLA frequency and prognosis in lung cancer. Br. J. Cancer. 43:1981;610-614.
36. Markman M., Braine H., Abeloff M.D. Histcompatability antigens in small cell carcinoma in lung cancer. Cancer. 54:1984;2943-2945.
37. Dellon A.Z., Rogentine G.N., Chreitien P.B. Prolonged survival in bronchogenic carcinoma associated with HLA antigens Aw 19 and HLAAS. J. Natl. Cancer Inst. 54:1975;1283-1286.
38. Futaki G., Kobayashi H., Sato K., Taneichi M., Katagiri M. Naturally processed HLA-DR9/DRS3 (DRB1*0901/DRB4*0101)-bound peptides. Immunogenetics. 42:1995;299-301.
39. Fujisao S., Matsushita S., Nishi T., Nishimura Y. Identification of HLA-DR9 (DRB1*0901)-binding peptide motifs using a phage fUSE5 random peptide library. Human Immunol. 45:1996;131-136.
40. Zhou G.-P., Guo Y.-Q., Ji Y.-H., Zhang G.-L. Major histocompatibility complex class II antigens in steroid-sensitive nephrotic syndrome in chinese children. Pediatr. Nephrol. 8:1994;140-141.
41. Hill A.V.S., Allsopp C.E.M., Kwiatkowski D., Anstey N.M., Twumasi P., Rowe P.A., Bennet S., Brewster D., McMichael A.J., Greenwood B.M. Nature (Lond.). 352:1991;595-600.
42. Thursz M.R., Kwiatkowski D., Allsopp C.E.M., Greenwood B.M., Thomas H.C., Hill A.V.S., Engl N. J. Med. 232:1995;1065-1069.
43. Apple R.J., Erlich H.A., Klitz, W., Manos M.M., Becker T.M., Wheeler C.M. associations with cervical carcinoma show papilloma virus-type specificity. Nat. Genet. 6:1994;157-162.
44. Davenport M.P., Quinn C.L., Chicz R.M., Green B.N., Willis A.C., Lane W.S., Bell J.I., Hill A.V.S. Naturally processed peptides from two disease-resistance-associated HLA-DR1 3 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DRβ chain. Proc. Natl. Acad. Sci. USA. 92:1995;6567-6571.
45. Shimura T., Hagihara M., Takebe K., Munkhbat B., Okada T., Kato H., Nagamachi Y., Tsuji K. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer. 73:1994;1184-1188.
46. Sastre-Garau X., Loste M.-N., Vincent-Salomon A., Favre M., Mouret E., Dela Rochefordiere A., Durand J.-C., Tartour E., Lepage V., Charron D. Decreased frequency of HLA-DRB1*13 alleles in French women with HPV-positive carcinoma of the cervix. Int. J. Cancer. 69:1996;159-164.
47. Coleman N., Stanley M.A. Characterization and functional analysis of the expression of vasculat adhesion molecules in human papilloma virus-related diseases of the cervix. Cancer. 14:1994;884-892.
48. Kerns B.M., Jordan P.A., Huper G., Marks J.R., Iglehart J.D., Layfield U. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin embedded breast cancer. Mod. Pathol. 6:1993;673-678.
49. Harpole D.H. Jr., Herndon J.E. II, Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.